Jorge Castriz, MD
Cardiovascular Disease · Great Falls, MTNPI 1811951601
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 40.6% of the total. 2025 is the largest year on record at $2,458, 9.9 times the $248 reported in 2019.
Across 125 payments — averaging $49.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$2K
- Novartis$306
- E.r. Squibb & Sons, L.L.C.$268
- Abiomed$150
- Impulse Dynamics (USA) Inc.$98
- plus $486 from 14 others
Across 7 payments — averaging $9572.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$67K
What the payments were for
- Travel & lodging$3,24252%
- Food & beverage$2,98448%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 36 | $2,532 |
| Medtronic(2 entities) | 19 | $2,401 |
| Novartis | 20 | $306 |
| E.r. Squibb & Sons, L.L.C. | 15 | $268 |
| Abiomed | 4 | $150 |
| Impulse Dynamics (USA) Inc. | 2 | $98 |
| W. L. Gore & Associates, Inc. | 2 | $92 |
| Amgen | 5 | $71 |
| Pfizer | 4 | $61 |
| Merck | 4 | $60 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $37 |
| GSK | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Shockwave Medical, Inc | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Bayer | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Philips North America LLC | 1 | $13 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,506
- AMPLATZER AMULET$1,468
- CoreValve Evolut$108
How this compares
$6,240 in reported general payments places this provider in the 75th percentile of 49 cardiovascular disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 437 | $377,154 |
| XareltoRivaroxaban | 125 | $150,603 |
| EntrestoSacubitril/Valsartan | 50 | $72,954 |
| Repatha SureclickEvolocumab | 17 | $22,268 |
| Metoprolol Succinate | 488 | $7,303 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 23 | $6,459 |
| Atorvastatin Calcium | 298 | $3,038 |
| Losartan Potassium | 187 | $2,132 |
| Digoxin | 76 | $2,019 |
| Carvedilol | 156 | $1,845 |
| Lisinopril | 146 | $1,325 |
| ClopidogrelClopidogrel Bisulfate | 114 | $1,289 |
| Flecainide Acetate | 39 | $1,054 |
| Torsemide | 28 | $1,053 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 52 | $934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $61 | $377,154437 claims |
| Johnson & JohnsonXarelto | $15 | $150,603125 claims |
| NovartisEntresto | $306 | $72,95450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 49 cardiovascular disease providers in Montana.
Other cardiovascular disease in Great Falls
- Alrich GrayGreat Falls$34K
- Michael RitchieGreat Falls$5K
- Miroslaw SochanskiGreat Falls$1K
- Benjamin PlankBillings$46K
- Robert MitchellKalispell$23K
- Jocelyn SpoonMissoula$17K
- Patricia KellyMissoula$12K
- Joseph ApostolBillings$12K
- Newton CoutinhoMissoula$10K
- Dane SobekBozeman$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.